AbbVie Inc (ABBV.N)
23 Apr 2014
|Market Cap (Mil.):||$79,818.47|
|Shares Outstanding (Mil.):||1,596.05|
* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie
- An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.
April 18 - An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.
LONDON - AbbVie, one of the two U.S. companies trying to stop Europe's drugs regulator from releasing previously secret clinical trials data, said on Thursday it had withdrawn lawsuits against the watchdog.
* Decision follows EMA acceptance of redactions to documents
LONDON, April 3 - AbbVie, one of the two U.S. firms bringing an injunction against Europe's drugs regulator over the issue of trial data secrecy, said on Thursday it had withdrawn its lawsuit.
Biosimilar drugs market
Feb 5 - U.S. drugmaker AbbVie Inc on Wednesday said it will spend $320 million to set up a manufacturing facility in Singapore to produce new drugs for cancer and immunology now in development.
- AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.
Jan 31 - AbbVie Inc on Friday reported lower fourth-quarter earnings, hurt by generic competition for its medicines, but results matched Wall Street expectations.